GO:0097696 cell surface receptor signaling pathway via STAT: Signaling Cascade, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097696 describes the intracellular signal transduction process in which STAT proteins convey signals from activated cell surface receptors to the nucleus to regulate gene expression.
• The pathway begins with receptor activation, followed by kinase-mediated STAT activation, STAT dimerization, nuclear translocation, and regulation of target gene expression.
• Core components include cytokine receptors, JAK kinases, STAT transcription factors, and negative regulators such as SOCS proteins.
• Dysregulation of this pathway is implicated in myelofibrosis, renal injury, melanoma immune evasion, and CAR T cell function.
• Research models for this pathway include knockout, point-mutation, knock-in, and overexpression cell lines, as well as CRISPR library screening.
• Understanding this pathway is essential for developing targeted therapies and optimizing immunotherapies.
Description
The cell surface receptor signaling pathway via STAT (GO:0097696) is a fundamental biological process that converts extracellular signals into changes in gene expression. This pathway is initiated when cytokines, growth factors, or interferons bind to cell surface receptors, leading to receptor activation and subsequent phosphorylation of STAT proteins by kinases such as JAKs. Once activated, STAT proteins dimerize and translocate to the nucleus, where they regulate the transcription of target genes involved in cell growth, differentiation, apoptosis, and immune responses. This pathway is highly conserved across evolution and plays critical roles in development and homeostasis. Researchers study this pathway to understand its contributions to diseases such as cancer, autoimmune disorders, and inflammatory conditions. The ability to manipulate this pathway using CRISPR-based models has become indispensable for dissecting its molecular mechanisms and identifying therapeutic targets.
cell surface receptor signaling pathway via STAT At A Glance
| GO ID | GO:0097696 |
|---|---|
| GO term | cell surface receptor signaling pathway via STAT |
| Ontology | biological_process |
| Synonym | kinase activated-STAT cascade; kinase-STAT cascade; receptor signaling pathway via STAT; STAT signalling pathway |
| Major function | Transduces extracellular signals from cell surface receptors to the nucleus via STAT proteins, regulating gene expression. |
| Key kinases | JAK family kinases (e.g., JAK1, JAK2, JAK3, TYK2) phosphorylate STAT proteins. |
| Key transcription factors | STAT family proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6). |
| Negative regulators | SOCS proteins (suppressors of cytokine signaling) and protein tyrosine phosphatases. |
| Evolutionary conservation | The CytoR/JAK/STAT/SOCS pathway emerged early in evolution and is conserved from invertebrates to mammals. |
What Is GO:0097696?
GO:0097696, cell surface receptor signaling pathway via STAT, is defined as an intracellular signal transduction process in which STAT proteins convey a signal to trigger a change in the activity or state of a cell. The cascade begins with receptor activation, followed by activation of STAT proteins by kinases. It proceeds through STAT dimerization and subsequent nuclear translocation of STAT proteins, and ends with regulation of target gene expression by STAT proteins.
Why Is cell surface receptor signaling pathway via STAT Important in Cell Biology?
The cell surface receptor signaling pathway via STAT is essential for normal development, immune function, and tissue homeostasis, and its dysregulation is a hallmark of many human diseases, including cancers, inflammatory disorders, and immunodeficiencies. Understanding this pathway provides critical insights into disease mechanisms and offers opportunities for therapeutic intervention, such as JAK inhibitors and STAT-targeted therapies.
• Regulates gene expression programs controlling cell proliferation, differentiation, survival, and apoptosis.
• Central to immune responses, including interferon signaling and cytokine-mediated inflammation.
• Implicated in hematological malignancies such as myelofibrosis, where JAK-STAT activation drives disease.
• Plays a role in renal injury and macrophage polarization, as shown in TREM2 deficiency models.
• Modulates CAR T cell effector functions, with Cullin-5 deficiency enhancing JAK/STAT signaling.
• Involved in melanoma immune evasion through type I interferon-induced PD-1 expression.
• Evolutionarily conserved, providing insights into fundamental signaling mechanisms.
• Target for small molecule inhibitors (e.g., JAK inhibitors) in clinical use.
• Key to understanding cytokine signaling in autoimmune and inflammatory diseases.
• Enables development of CRISPR-based models to study gene function and drug resistance.
What Happens During cell surface receptor signaling pathway via STAT?
Receptor Activation and Kinase Recruitment
In simple terms: A signal molecule binds to a receptor on the cell surface, causing the receptor to activate and attract kinases.
The pathway begins when extracellular ligands such as cytokines, interferons, or growth factors bind to their specific cell surface receptors. This binding induces receptor dimerization or conformational changes, leading to activation of receptor-associated kinases, primarily of the JAK family (JAK1, JAK2, JAK3, TYK2). These kinases phosphorylate tyrosine residues on the receptor cytoplasmic domains, creating docking sites for STAT proteins.
STAT Protein Activation and Dimerization
In simple terms: STAT proteins are recruited to the receptor, get phosphorylated, and pair up.
STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6) are recruited to the phosphorylated receptor via their SH2 domains. JAK kinases then phosphorylate a critical tyrosine residue on the STAT proteins, causing them to dissociate from the receptor and form dimers through SH2-phosphotyrosine interactions. This dimerization is essential for their subsequent nuclear translocation.
Nuclear Translocation and DNA Binding
In simple terms: The paired STAT proteins move into the nucleus and bind to DNA.
Phosphorylated STAT dimers translocate from the cytoplasm to the nucleus through nuclear pore complexes. Inside the nucleus, they bind to specific DNA sequences in the promoter regions of target genes, often as dimers or tetramers, to regulate transcription. This step is tightly regulated by nuclear import and export signals.
Regulation of Target Gene Expression
In simple terms: STAT proteins turn target genes on or off, changing cell behavior.
Once bound to DNA, STAT dimers recruit transcriptional coactivators or corepressors to modulate the expression of target genes involved in diverse processes such as cell cycle progression, apoptosis, immune response, and differentiation. The specific genes activated depend on the STAT family member, cell type, and context.
Negative Feedback and Termination
In simple terms: The signal is shut off by inhibitor proteins to prevent overactivity.
The pathway is terminated by negative regulators, including SOCS (suppressors of cytokine signaling) proteins and protein tyrosine phosphatases (PTPs). SOCS proteins are induced by STAT signaling and bind to JAKs or receptors to inhibit further phosphorylation, creating a negative feedback loop. This regulation is crucial to prevent excessive or prolonged signaling.
Key Genes Involved in GO:0097696 cell surface receptor signaling pathway via STAT
The following genes and proteins are central to the cell surface receptor signaling pathway via STAT, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| JAK1 | Non-receptor tyrosine kinase that phosphorylates STAT proteins | Target for autoimmune and cancer therapies; knockout models show impaired cytokine signaling. |
| JAK2 | Kinase essential for hematopoietic cytokine signaling; phosphorylates STAT5 | Mutations linked to myeloproliferative neoplasms; key target in myelofibrosis. |
| JAK3 | Kinase primarily in immune cells; mediates IL-2 family signaling | Immunodeficiency and leukemia research; knockout affects T cell development. |
| TYK2 | Kinase involved in type I interferon and IL-12 signaling | Autoimmune disease associations; knockout reduces interferon responses. |
| STAT1 | Transcription factor mediating interferon and immune responses | Knockout increases susceptibility to infections; cancer immunology studies. |
| STAT2 | Transcription factor in type I interferon signaling | Antiviral responses; knockout impairs interferon-stimulated gene expression. |
| STAT3 | Transcription factor regulating proliferation, survival, and inflammation | Oncogene in many cancers; knockout is embryonic lethal; conditional models widely used. |
| STAT4 | Transcription factor for Th1 differentiation and IL-12 signaling | Autoimmune and inflammatory disease models; knockout alters T cell responses. |
| STAT5A | Transcription factor in hematopoiesis and mammary gland development | Knockout affects prolactin signaling; cancer research. |
| STAT5B | Transcription factor in growth hormone and immune signaling | Knockout causes growth defects; cancer and immune studies. |
| STAT6 | Transcription factor for IL-4 and IL-13 signaling | Allergy and asthma models; knockout impairs Th2 responses. |
| SOCS1 | Negative regulator of JAK-STAT signaling | Knockout leads to excessive inflammation; cancer and autoimmunity research. |
| SOCS3 | Negative regulator of JAK-STAT signaling | Knockout is embryonic lethal; conditional models show metabolic and immune roles. |
| CUL5 | Component of E3 ubiquitin ligase complex modulating JAK/STAT | Deficiency enhances CAR T cell function via JAK/STAT modulation. |
| TREM2 | Receptor modulating macrophage polarization via JAK-STAT | Deficiency aggravates renal injury; knockout models available. |
| PD-1 (PDCD1) | Immune checkpoint induced by type I interferon via STAT signaling | Melanoma immune evasion; knockout and overexpression models. |
| IL6 | Cytokine activating JAK-STAT3 signaling | Inflammation and cancer; knockout and overexpression models. |
| IL22 | Cytokine activating STAT3 in epithelial cells | Tissue repair and inflammation; knockout models. |
How Is cell surface receptor signaling pathway via STAT Regulated?
The cell surface receptor signaling pathway via STAT is tightly regulated at multiple levels. Negative feedback is primarily mediated by SOCS proteins, which are induced by STAT signaling and inhibit JAK kinase activity or compete for receptor binding sites. Protein tyrosine phosphatases (PTPs) such as SHP-1 and CD45 also dephosphorylate JAKs and STATs to terminate signaling. Additionally, PIAS (protein inhibitor of activated STAT) proteins inhibit STAT DNA binding and promote SUMOylation. The pathway is also modulated by ubiquitin-proteasome degradation, as seen with Cullin-5 deficiency enhancing JAK/STAT signaling in CAR T cells. Cross-talk with other signaling pathways, such as mTOR and MAPK, further fine-tunes STAT activity.
cell surface receptor signaling pathway via STAT and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| JAK2 | Myelofibrosis, polycythemia vera | Knock-in of JAK2 V617F mutation in hematopoietic stem cells |
| TREM2 | Renal injury, macrophage apoptosis | TREM2 knockout mice or cell lines |
| CUL5 | CAR T cell effector function | CUL5 knockout CAR T cells |
| PDCD1 (PD-1) | Melanoma immune evasion | PD-1 knockout or overexpression in melanoma cells |
| STAT3 | Inflammation, cancer | STAT3 knockout or point-mutation cell lines |
Myelofibrosis and Myeloproliferative Neoplasms
Constitutive activation of JAK-STAT signaling, often due to JAK2 V617F or CALR mutations, drives myelofibrosis and other myeloproliferative neoplasms. Targeted therapies such as JAK inhibitors (e.g., ruxolitinib) are used clinically, but resistance and incomplete responses necessitate ongoing research into combination therapies and novel targets.
Renal Injury and Macrophage Polarization
TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway. This highlights the role of STAT signaling in kidney disease and suggests that modulating this pathway could be therapeutic.
Cancer Immunotherapy and CAR T Cells
Cullin-5 deficiency enhances CAR T cell effector functions via modulation of JAK/STAT signaling, indicating that this pathway can be targeted to improve adoptive cell therapies. In melanoma, type I interferon signaling induces PD-1 expression through STAT activation, contributing to immune checkpoint blockade resistance.
Inflammatory and Autoimmune Diseases
Dysregulated IL-6 and IL-22 signaling through STAT3 contributes to chronic inflammation and autoimmune conditions. Understanding these mechanisms has led to JAK inhibitors for diseases such as rheumatoid arthritis and psoriasis.
From cell surface receptor signaling pathway via STAT-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of JAK2 affect cytokine signaling? | JAK2 knockout cell line (e.g., HEK293) |
| Does a specific STAT3 mutation alter DNA binding? | STAT3 point-mutation knock-in cell line |
| Can we tag STAT1 to track nuclear translocation? | STAT1 knock-in with fluorescent tag |
| Does overexpression of SOCS1 suppress STAT signaling? | SOCS1 overexpression cell line |
| Which genes are essential for STAT3-mediated transcription? | CRISPR library screening in STAT3-dependent cells |
| Does CUL5 knockout enhance CAR T cell function? | CUL5 knockout primary T cells |
How to Study the cell surface receptor signaling pathway via STAT Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify STAT target genes |
| Phospho-Western blot | Phosphorylation of JAK/STAT proteins | Validate pathway activation |
| Immunofluorescence | Subcellular localization of STATs | Track nuclear translocation |
| CRISPR library screening | Gene essentiality and pathway modifiers | Discover regulators of STAT signaling |
| Co-immunoprecipitation | Protein-protein interactions | Study STAT dimerization and complex formation |
| ChIP-seq | STAT DNA binding sites | Map STAT binding across the genome |
| Flow cytometry | Cell surface markers and viability | Assess immune cell responses |
Transcriptional Profiling (RNA-seq)
RNA sequencing measures global gene expression changes upon pathway activation or perturbation. It is used to identify STAT target genes and assess the impact of knockouts or mutations in pathway components.
Phospho-Proteomics and Western Blotting
These methods detect phosphorylation of JAKs and STATs, providing direct evidence of pathway activation. They are essential for validating knockout or point-mutation effects.
Imaging and Nuclear Translocation Assays
Fluorescence microscopy with tagged STAT proteins allows visualization of dimerization and nuclear translocation in live cells, offering spatial and temporal insights.
CRISPR Library Screening
Genome-wide CRISPR screens identify genes that modulate STAT signaling, such as negative regulators or synthetic lethal partners. This approach is powerful for discovering new therapeutic targets.
How CRISPR Can Be Used to Study GO:0097696 cell surface receptor signaling pathway via STAT
Knockout
CRISPR knockout is used to completely ablate genes such as JAK2, STAT3, or SOCS1 to study their roles in the pathway. For example, JAK2 knockout cells show impaired cytokine-induced STAT phosphorylation. Knockout of CUL5 enhances CAR T cell function via JAK/STAT modulation.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants, such as JAK2 V617F, or to disrupt specific phosphorylation sites on STAT proteins. These models help dissect the contribution of individual residues to pathway activity.
Knock-in
Knock-in of tagged versions of STAT proteins (e.g., GFP-STAT1) allows real-time tracking of localization and interactions. Knock-in of reporter genes under STAT-responsive promoters enables monitoring of pathway activity.
Overexpression
Overexpression of wild-type or mutant STATs, JAKs, or SOCS proteins is used to study gain-of-function effects and to model diseases with elevated pathway activity, such as myelofibrosis.
How EDITGENE Supports cell surface receptor signaling pathway via STAT Research
Researchers studying cell surface receptor signaling pathway via STAT-related genes often need to determine whether a candidate gene is causally involved in pathway regulation or disease. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for cell surface receptor signaling pathway via STAT research.
Frequently Asked Questions About cell surface receptor signaling pathway via STAT
What is the cell surface receptor signaling pathway via STAT?
It is a biological process (GO:0097696) where STAT proteins transmit signals from activated cell surface receptors to the nucleus, regulating gene expression.
What genes are involved in the STAT signaling pathway?
Key genes include JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, and SOCS1-7.
How does the JAK-STAT pathway work?
Cytokines bind receptors, activating JAK kinases that phosphorylate STATs. STATs dimerize, enter the nucleus, and activate target genes.
What diseases are associated with STAT signaling?
Myelofibrosis, renal injury, melanoma, autoimmune diseases, and immunodeficiencies.
What are the negative regulators of STAT signaling?
SOCS proteins and protein tyrosine phosphatases (PTPs) terminate the signal.
How can I study STAT signaling in the lab?
Use CRISPR knockouts, point mutations, knock-ins, overexpression, RNA-seq, phospho-proteomics, and imaging.
What is the role of STAT3 in cancer?
STAT3 is constitutively active in many cancers, promoting proliferation and survival.
Can CRISPR be used to model JAK2 V617F mutation?
Yes, CRISPR knock-in can introduce the JAK2 V617F point mutation to model myeloproliferative neoplasms.
What is the evolutionary origin of the JAK-STAT pathway?
The CytoR/JAK/STAT/SOCS pathway emerged early in evolution and is conserved across metazoans.
How does Cullin-5 affect CAR T cells?
Cullin-5 deficiency enhances CAR T cell effector functions via modulation of JAK/STAT signaling.
Conclusion
The cell surface receptor signaling pathway via STAT (GO:0097696) is a central mechanism for transducing extracellular signals into gene expression changes. Its dysregulation underlies numerous diseases, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and screening technologies continue to illuminate its complexities and provide new avenues for drug discovery.
References
- 1. Loscocco GG et al.. 2025. Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.. Am J Hematol 100 Suppl 4(Suppl 4):30-50 PMID: 40062529
- 2. Cui Y et al.. 2024. TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway in mice.. Cell Death Dis 15(6):401 PMID: 38849370
- 3. Adachi Y et al.. 2024. Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway.. Nat Commun 15(1):10376 PMID: 39658572
- 4. Heinrich PC et al.. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation.. Biochem J 374(Pt 1):1-20 PMID: 12773095
- 5. Holzgruber J et al.. 2024. Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade.. Nat Commun 15(1):7165 PMID: 39187481
- 6. Wolk K et al.. 2010. Biology of interleukin-22.. Semin Immunopathol 32(1):17-31 PMID: 20127093
- 7. Liongue C et al.. 2016. Evolution of Cytokine Receptor Signaling.. J Immunol 197(1):11-8 PMID: 27317733
- 8. Liongue C et al.. 2016. Signaling via the CytoR/JAK/STAT/SOCS pathway: Emergence during evolution.. Mol Immunol 71:166-175 PMID: 26897340
